Oncolytics Advances Pelareorep Toward Anal Cancer Approval
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
